背景：T 细胞淋巴瘤（TCL）是一组异质性癌症，其反应率和持续时间均较差。这些癌症的风险分层仍然面临巨大挑战。分化簇 (CD) 5 在 B 细胞淋巴瘤的许多亚型中显示出预后意义；然而，其在 TCL 中的作用尚不清楚。方法：我们对新诊断的 TCL 患者进行单机构回顾性分析。 CD5 阳性是根据免疫组织化学和/或流式细胞术的阳性结果确定的。我们使用生物因素的单变量和多变量分析来评估它们与生存结果的关联。结果：共鉴定出 194 名 TCL 患者，涵盖 14 个亚型。 63% 的患者呈 CD5 阳性，其中 TFH TCL (93.9%)、PTCL-NOS (82.9%) 和 ATLL (77.8%) 中 CD5 表达比例最高 (p = 0.00004)。诊断时年龄较大 (p = 0.001)、III 期或 IV 期疾病 (p = 0.05) 和骨髓受累 (p = 0.003) 也与 CD5 表达相关。所有亚型的 CD5 TCL 患者的完全缓解率均较低。 OS/PFS 与整个队列中的 CD5 状态没有统计学相关性；然而，CD5 TFH TCL (p = 0.04) 和 CD5 ATLL (p = 0.04) 患者的 OS 显着降低。结论：本研究首次将 CD5 表达作为 TCL 预后的生物标志物进行检验。 CD5 在西方世界最常见的淋巴结 TCL 中频繁表达，这支撑了其作为细胞治疗有吸引力的靶标的潜力。计划在更大的队列中确认这些发现，并研究解释我们的观察结果的潜在病理生理机制。

Background: T-cell lymphomas (TCLs) are a group of heterogenous cancers with poor rates and duration of response. There remains a great challenge in risk stratification of these cancers. Cluster of differentiation (CD) 5 has shown prognostic implication in many subtypes of B-cell lymphoma; however, its role in TCLs is not known. Methods: We performed a single-institution retrospective analysis of newly diagnosed patients with TCL. CD5 positivity was determined based on positive results via immunohistochemistry and/or flow cytometry. We used univariate and multivariable analysis of biological factors to assess their association with survival outcomes. Results: A total of 194 patients with TCL spanning 14 subtypes were identified. CD5 positivity was noted in 63% of patients, with the highest proportion of CD5 expression in TFH TCL (93.9%), PTCL-NOS (82.9%), and ATLL (77.8%) (p = 0.00004). Older age at diagnosis (p = 0.001), stage III or IV disease (p = 0.05), and bone marrow involvement (p = 0.003) were also associated with CD5 expression. Complete response rates were numerically lower in patients with CD5+ TCL across all subtypes. OS/PFS was not statistically associated with CD5 status in the overall cohort; however there was significantly decreased OS in CD5+ TFH TCL (p = 0.04) and CD5+ ATLL (p = 0.04) patients. Conclusions: This study represents the first to examine CD5 expression as a prognostic biomarker for outcomes in TCL. The frequent expression of CD5 in the most common nodal TCL in the Western world underpins its potential as an attractive target for cellular therapies. Confirmation of these findings in a larger cohort and investigation of potential pathophysiological mechanisms explaining our observations are planned.